The cost of sequencing human genome has fallen from $100M to under $100 in approximately 25 years

Element Biosciences has reportedly achieved a landmark breakthrough in genomics, hitting the long-anticipated $100 human genome sequencing milestone as of February 2026. This price point represents a staggering 1,000,000x cost reduction from the original $100 million Human Genome Project completed in 2000, and a 10x drop from the $1,000 genome milestone reached around 2014. The pace of this cost deflation has dramatically outpaced Moore's Law, which observed a doubling of computing power every two years.

The technical achievement by Element Biosciences, a company developing novel DNA sequencing platforms, signifies a transition from expensive, specialized medical testing to a commodity-scale diagnostic tool. For context, sequencing a genome for $100 makes it comparable in cost to many standard blood panels or imaging tests. This collapse in price is driven by continuous innovations in sequencing chemistry, fluidics, optics, and data analysis algorithms, allowing for faster, higher-throughput, and more accurate reading of DNA.

This milestone fundamentally alters the economics of healthcare and biomedical research. At this price, population-scale genomic screening becomes financially viable for public health initiatives, enabling the identification of genetic risk factors for common diseases like cancer, heart disease, and diabetes on an unprecedented scale. It moves genomics from reactive diagnostics—used only after symptoms appear—to proactive, preventative care. Researchers can now sequence vast cohorts to uncover the genetic underpinnings of complex traits and diseases with new statistical power, accelerating drug discovery and the development of targeted therapies.